BIRC3 and colorectal carcinoma: In this study, we observed that the KY1022 treatment effectively suppresses API-2-induced cell-migration ability via the destabilization of β-catenin, co-accumulated with FOXO3 in the nucleus of the CRC cells harboring APC mutation.